Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- Submitting institution
-
Cardiff University / Prifysgol Caerdydd
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 101943226
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(19)30817-4
- Title of journal
- Lancet Oncology
- Article number
- -
- First page
- 345
- Volume
- 21
- Issue
- 3
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- February
- Year of publication
- 2020
- URL
-
https://doi.org/10.1016/S1470-2045%2819%2930817-4
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
15
- Research group(s)
-
-
- Citation count
- 28
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
